Compare Sterling Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GSK PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GSK PHARMA STERLING BIOTECH/
GSK PHARMA
 
P/E (TTM) x -0.4 51.1 - View Chart
P/BV x 0.0 11.5 0.1% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 STERLING BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GSK PHARMA
Mar-19
STERLING BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs113,595 0.3%   
Low Rs31,253 0.3%   
Sales per share (Unadj.) Rs26.8184.7 14.5%  
Earnings per share (Unadj.) Rs-15.026.3 -56.9%  
Cash flow per share (Unadj.) Rs-5.529.2 -18.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs54.9126.3 43.4%  
Shares outstanding (eoy) m267.87169.40 158.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.313.1 2.0%   
Avg P/E ratio x-0.592.2 -0.5%  
P/CF ratio (eoy) x-1.383.1 -1.5%  
Price / Book Value ratio x0.119.2 0.7%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m1,862410,626 0.5%   
No. of employees `0001.45.0 27.3%   
Total wages/salary Rs m5475,372 10.2%   
Avg. sales/employee Rs Th5,303.36,306.7 84.1%   
Avg. wages/employee Rs Th403.81,083.1 37.3%   
Avg. net profit/employee Rs Th-2,959.0898.0 -329.5%   
INCOME DATA
Net Sales Rs m7,18131,281 23.0%  
Other income Rs m431,023 4.2%   
Total revenues Rs m7,22332,304 22.4%   
Gross profit Rs m9476,009 15.8%  
Depreciation Rs m2,543486 523.3%   
Interest Rs m4,3776 72,951.7%   
Profit before tax Rs m-5,9316,540 -90.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m-1,9242,373 -81.1%   
Profit after tax Rs m-4,0074,454 -90.0%  
Gross profit margin %13.219.2 68.6%  
Effective tax rate %32.436.3 89.4%   
Net profit margin %-55.814.2 -391.9%  
BALANCE SHEET DATA
Current assets Rs m14,33520,061 71.5%   
Current liabilities Rs m49,80914,543 342.5%   
Net working cap to sales %-494.017.6 -2,800.5%  
Current ratio x0.31.4 20.9%  
Inventory Days Days40357 710.5%  
Debtors Days Days17114 1,213.7%  
Net fixed assets Rs m55,43214,343 386.5%   
Share capital Rs m2681,694 15.8%   
"Free" reserves Rs m13,93519,704 70.7%   
Net worth Rs m14,70121,398 68.7%   
Long term debt Rs m9,4782 473,892.5%   
Total assets Rs m73,98839,113 189.2%  
Interest coverage x-0.41,091.0 -0.0%   
Debt to equity ratio x0.60 689,771.0%  
Sales to assets ratio x0.10.8 12.1%   
Return on assets %0.511.4 4.4%  
Return on equity %-27.320.8 -130.9%  
Return on capital %-6.431.9 -20.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860534 348.3%   
Fx outflow Rs m257,091 0.4%   
Net fx Rs m1,835-6,557 -28.0%   
CASH FLOW
From Operations Rs m1,7193,994 43.0%  
From Investments Rs m-3,148-1,433 219.6%  
From Financial Activity Rs m1,426-3,584 -39.8%  
Net Cashflow Rs m-3-1,023 0.3%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 9.9 23.8 41.6%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 15.4 255.2%  
Shareholders   21,482 102,036 21.1%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  NATCO PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

4 Reasons Why Sensex Surged 750 Points Today(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS